FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567117613> ?p ?o ?g. }

• W2567117613 endingPage "58" @default.
• W2567117613 startingPage "38" @default.
• W2567117613 abstract "Chimeric antigen receptor (CAR) gene-engineered T cell therapy holds the potential to make a meaningful difference in the lives of patients with terminal cancers. For decades, cancer therapy was based on biophysical parameters, with surgical resection to debulk, followed by radiation and chemotherapy to target the rapidly growing tumor cells, while mostly sparing quiescent normal tissues. One breakthrough occurred with allogeneic bone-marrow transplant for patients with leukemia, which provided a sometimes curative therapy. The field of adoptive cell therapy for solid tumors was established with the discovery that tumor-infiltrating lymphocytes could be expanded and used to treat and even cure patients with metastatic melanoma. Tumor-specific T-cell receptors (TCRs) were identified and engineered into patient peripheral blood lymphocytes, which were also found to treat tumors. However, these were limited by patient HLA-restriction. Close behind came generation of CAR, combining the exquisite recognition of an antibody with the effector function of a T cell. The advent of CD19-targeted CARs for treating patients with multiple forms of advanced B-cell malignancies met with great success, with up to 95% response rates. Applying CAR treatment to solid tumors, however, has just begun, but already certain factors have been made clear: the tumor target is of utmost importance for clinicians to do no harm; and solid tumors respond differently to CAR therapy compared with hematologic ones. Here we review the state of clinical gene-engineered T cell immunotherapy, its successes, challenges, and future." @default.
• W2567117613 created "2017-01-06" @default.
• W2567117613 creator A5008558372 @default.
• W2567117613 creator A5090670583 @default.
• W2567117613 date "2016-12-27" @default.
• W2567117613 modified "2023-10-14" @default.
• W2567117613 title "Driving gene-engineered T cell immunotherapy of cancer" @default.
• W2567117613 cites W1442200272 @default.
• W2567117613 cites W1541816872 @default.
• W2567117613 cites W1589789540 @default.
• W2567117613 cites W1619537825 @default.
• W2567117613 cites W1647507681 @default.
• W2567117613 cites W1767113662 @default.
• W2567117613 cites W1800095175 @default.
• W2567117613 cites W1828443506 @default.
• W2567117613 cites W1842126375 @default.
• W2567117613 cites W1877911682 @default.
• W2567117613 cites W1916979945 @default.
• W2567117613 cites W1944166248 @default.
• W2567117613 cites W1956825767 @default.
• W2567117613 cites W1963522404 @default.
• W2567117613 cites W1965029629 @default.
• W2567117613 cites W1966542058 @default.
• W2567117613 cites W1967517831 @default.
• W2567117613 cites W1969438318 @default.
• W2567117613 cites W1971746066 @default.
• W2567117613 cites W1974431455 @default.
• W2567117613 cites W1978670809 @default.
• W2567117613 cites W1983143892 @default.
• W2567117613 cites W1984287161 @default.
• W2567117613 cites W1989273697 @default.
• W2567117613 cites W1991890073 @default.
• W2567117613 cites W2003197307 @default.
• W2567117613 cites W2006428939 @default.
• W2567117613 cites W2008324933 @default.
• W2567117613 cites W2009914447 @default.
• W2567117613 cites W2010607826 @default.
• W2567117613 cites W2016789384 @default.
• W2567117613 cites W2020312840 @default.
• W2567117613 cites W2021472146 @default.
• W2567117613 cites W2027863358 @default.
• W2567117613 cites W2030099809 @default.
• W2567117613 cites W2034528738 @default.
• W2567117613 cites W2039123767 @default.
• W2567117613 cites W2039721940 @default.
• W2567117613 cites W2042541303 @default.
• W2567117613 cites W2045475405 @default.
• W2567117613 cites W2045720696 @default.
• W2567117613 cites W2047205338 @default.
• W2567117613 cites W2050085247 @default.
• W2567117613 cites W2050302632 @default.
• W2567117613 cites W2050386410 @default.
• W2567117613 cites W2050407789 @default.
• W2567117613 cites W2051549641 @default.
• W2567117613 cites W2052587346 @default.
• W2567117613 cites W2054609442 @default.
• W2567117613 cites W2063184115 @default.
• W2567117613 cites W2064272625 @default.
• W2567117613 cites W2064342667 @default.
• W2567117613 cites W2064510700 @default.
• W2567117613 cites W2065635440 @default.
• W2567117613 cites W2067016959 @default.
• W2567117613 cites W2068302119 @default.
• W2567117613 cites W2068890283 @default.
• W2567117613 cites W2070748533 @default.
• W2567117613 cites W2074327759 @default.
• W2567117613 cites W2076991609 @default.
• W2567117613 cites W2080040601 @default.
• W2567117613 cites W2082708772 @default.
• W2567117613 cites W2085898109 @default.
• W2567117613 cites W2087055812 @default.
• W2567117613 cites W2087857484 @default.
• W2567117613 cites W2090342830 @default.
• W2567117613 cites W2094652659 @default.
• W2567117613 cites W2094945699 @default.
• W2567117613 cites W2097175022 @default.
• W2567117613 cites W2097995306 @default.
• W2567117613 cites W2098852858 @default.
• W2567117613 cites W2099570622 @default.
• W2567117613 cites W2099694564 @default.
• W2567117613 cites W2101653483 @default.
• W2567117613 cites W2104597364 @default.
• W2567117613 cites W2105400883 @default.
• W2567117613 cites W2105879190 @default.
• W2567117613 cites W2106582884 @default.
• W2567117613 cites W2107806760 @default.
• W2567117613 cites W2110641339 @default.
• W2567117613 cites W2112121482 @default.
• W2567117613 cites W2112723216 @default.
• W2567117613 cites W2114147900 @default.
• W2567117613 cites W2114634050 @default.
• W2567117613 cites W2118323175 @default.
• W2567117613 cites W2118796952 @default.
• W2567117613 cites W2118982164 @default.
• W2567117613 cites W2119819636 @default.
• W2567117613 cites W2121315503 @default.
• W2567117613 cites W2123363005 @default.
• W2567117613 cites W2124513722 @default.

• next